Bavarian Nordic A/S

BAVA

DK0015998017

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 26/06/2024 BST			5-day change	1st Jan Change
182.8 ^DKK	+17.14%		+15.55%	+3.01%

07:21pm	Congo authorities approve mpox vaccines to try to contain outbreak	RE
11:58am	Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate	MT

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

May 21, 2024 at 01:00 pm

Bavarian Nordic A/S announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Company to pursue new opportunities. She will continue to support Bavarian Nordic until the end of May 2024. The Company will initiate a search process to identify the next Chief Medical Officer.

Latest news about Bavarian Nordic A/S

Congo authorities approve mpox vaccines to try to contain outbreak	06:21pm	RE
Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate	10:58am	MT
Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema	09:26am	CI
Bavarian Nordic Wraps Up US FDA's Biologics License Application for Chikungunya Vaccine Candidate	06-18	MT
High-risk health workers can get routine Ebola vaccine, Gavi says	06-13	RE
High-risk health workers can get routine Ebola vaccine, says Gavi	06-13	RE
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine	05-31	MT
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children	05-30	MT
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa	05-30	CI
Bavarian Nordic’s Medical Chief to Step Down by May-end	05-21	MT
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer	05-21	CI
Transcript : Bavarian Nordic A/S, Q1 2024 Earnings Call, May 08, 2024	05-08
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.	05-08	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024	05-08	CI
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine	04-30	MT
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve	04-29	CI
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate	04-29	MT
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate	04-29	CI
Bavarian Nordic A/S's Equity Buyback announced on May 9, 2023, has expired.	04-15	CI
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	03-13	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	03-13	CI
Nordic Shares Moved Upward Wednesday; BoneSupport Holding Topped Leaders	03-06	DJ
Transcript : Bavarian Nordic A/S, 2023 Earnings Call, Mar 06, 2024	03-06
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI

Chart Bavarian Nordic A/S

Duration

Period

More charts

Company Profile

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

182.8 DKK

Average target price

263.2 DKK

Spread / Average Target

+43.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAVARIAN NORDIC A/S	+3.01%	1.74B
ELI LILLY AND COMPANY	+54.61%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+20.62%	337B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+8.61%	171B

Other Pharmaceuticals

Bavarian Nordic A/S

Equities

BAVA

DK0015998017

Pharmaceuticals

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

EPS Revisions